Literature DB >> 25280969

WHSC1 promotes oncogenesis through regulation of NIMA-related kinase-7 in squamous cell carcinoma of the head and neck.

Vassiliki Saloura1, Hyun-Soo Cho2, Kazuma Kiyotani1, Houda Alachkar1, Zhixiang Zuo1, Makoto Nakakido1, Tatsuhiko Tsunoda3, Tanguy Seiwert1, Mark Lingen1, Jonathan Licht4, Yusuke Nakamura1, Ryuji Hamamoto5.   

Abstract

UNLABELLED: Squamous cell carcinoma of the head and neck (SCCHN) is a relatively common malignancy with suboptimal long-term prognosis, thus new treatment strategies are urgently needed. Over the last decade, histone methyltransferases (HMT) have been recognized as promising targets for cancer therapy, but their mechanism of action in most solid tumors, including SCCHN, remains to be elucidated. This study investigated the role of Wolf-Hirschhorn syndrome candidate 1 (WHSC1), an NSD family HMT, in SCCHN. Immunohistochemical analysis of locoregionally advanced SCCHN, dysplastic, and normal epithelial tissue specimens revealed that WHSC1 expression and dimethylation of histone H3 lysine 36 (H3K36me2) were significantly higher in SCCHN tissues than in normal epithelium. Both WHSC1 expression and H3K36me2 levels were significantly correlated with histologic grade. WHSC1 knockdown in multiple SCCHN cell lines resulted in significant growth suppression, induction of apoptosis, and delay of the cell-cycle progression. Immunoblot and immunocytochemical analyses in SCCHN cells demonstrated that WHSC1 induced H3K36me2 and H3K36me3. Microarray expression profile analysis revealed NIMA-related kinase-7 (NEK7) to be a downstream target gene of WHSC1, and chromatin immunoprecipitation (ChIP) assays showed that NEK7 was directly regulated by WHSC1 through H3K36me2. Furthermore, similar to WHSC1, NEK7 knockdown significantly reduced cell-cycle progression, indicating that NEK7 is a key player in the molecular pathway regulated by WHSC1. IMPLICATIONS: WHSC1 possesses oncogenic functions in SCCHN and represents a potential molecular target for the treatment of SCCHN. ©2014 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25280969     DOI: 10.1158/1541-7786.MCR-14-0292-T

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  44 in total

1.  AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis.

Authors:  Ni Li; Wei Xue; Huairui Yuan; Baijun Dong; Yufeng Ding; Yongfeng Liu; Min Jiang; Shan Kan; Tongyu Sun; Jiale Ren; Qiang Pan; Xiang Li; Peiyuan Zhang; Guohong Hu; Yan Wang; Xiaoming Wang; Qintong Li; Jun Qin
Journal:  J Clin Invest       Date:  2017-03-20       Impact factor: 14.808

2.  Lentiviral vector-mediated insertional mutagenesis screen identifies genes that influence androgen independent prostate cancer progression and predict clinical outcome.

Authors:  Arun K Nalla; Theodore F Williams; Casey P Collins; Dustin T Rae; Grant D Trobridge
Journal:  Mol Carcinog       Date:  2015-10-29       Impact factor: 4.784

3.  Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas.

Authors:  Simon Papillon-Cavanagh; Chao Lu; Tenzin Gayden; Leonie G Mikael; Denise Bechet; Christina Karamboulas; Laurie Ailles; Jason Karamchandani; Dylan M Marchione; Benjamin A Garcia; Ilan Weinreb; David Goldstein; Peter W Lewis; Octavia Maria Dancu; Sandeep Dhaliwal; William Stecho; Christopher J Howlett; Joe S Mymryk; John W Barrett; Anthony C Nichols; C David Allis; Jacek Majewski; Nada Jabado
Journal:  Nat Genet       Date:  2017-01-09       Impact factor: 38.330

4.  High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2.

Authors:  Nathan P Coussens; Stephen C Kales; Mark J Henderson; Olivia W Lee; Kurumi Y Horiuchi; Yuren Wang; Qing Chen; Ekaterina Kuznetsova; Jianghong Wu; Sirisha Chakka; Dorian M Cheff; Ken Chih-Chien Cheng; Paul Shinn; Kyle R Brimacombe; Min Shen; Anton Simeonov; Madhu Lal-Nag; Haiching Ma; Ajit Jadhav; Matthew D Hall
Journal:  J Biol Chem       Date:  2018-06-26       Impact factor: 5.157

5.  Inhibition of SETMAR-H3K36me2-NHEJ repair axis in residual disease cells prevents glioblastoma recurrence.

Authors:  Ekjot Kaur; Jyothi Nair; Atanu Ghorai; Saket V Mishra; Anagha Achareker; Madhura Ketkar; Debashmita Sarkar; Sameer Salunkhe; Jacinth Rajendra; Nilesh Gardi; Sanket Desai; Prajish Iyer; Rahul Thorat; Amit Dutt; Aliasgar Moiyadi; Shilpee Dutt
Journal:  Neuro Oncol       Date:  2020-12-18       Impact factor: 12.300

Review 6.  NEK7: a new target for the treatment of multiple tumors and chronic inflammatory diseases.

Authors:  Jin Wang; Simeng Chen; Min Liu; Min Zhang; Xiaoyi Jia
Journal:  Inflammopharmacology       Date:  2022-07-13       Impact factor: 5.093

Review 7.  The role of NSD1, NSD2, and NSD3 histone methyltransferases in solid tumors.

Authors:  Iuliia Topchu; Rajendra P Pangeni; Igor Bychkov; Sven A Miller; Evgeny Izumchenko; Jindan Yu; Erica Golemis; John Karanicolas; Yanis Boumber
Journal:  Cell Mol Life Sci       Date:  2022-05-09       Impact factor: 9.207

8.  Bisphenol A Disrupts HNF4α-Regulated Gene Networks Linking to Prostate Preneoplasia and Immune Disruption in Noble Rats.

Authors:  Hung-Ming Lam; Shuk-Mei Ho; Jing Chen; Mario Medvedovic; Neville Ngai Chung Tam
Journal:  Endocrinology       Date:  2015-10-23       Impact factor: 4.736

Review 9.  Integrated Analysis of Whole Genome and Epigenome Data Using Machine Learning Technology: Toward the Establishment of Precision Oncology.

Authors:  Ken Asada; Syuzo Kaneko; Ken Takasawa; Hidenori Machino; Satoshi Takahashi; Norio Shinkai; Ryo Shimoyama; Masaaki Komatsu; Ryuji Hamamoto
Journal:  Front Oncol       Date:  2021-05-12       Impact factor: 6.244

10.  NEK7 Promotes Pancreatic Cancer Progression And Its Expression Is Correlated With Poor Prognosis.

Authors:  Zilong Yan; Jianhua Qu; Zhangfu Li; Jing Yi; Yanze Su; Qirui Lin; Guangyin Yu; Zewei Lin; Weihua Yin; Fengmin Lu; Jikui Liu
Journal:  Front Oncol       Date:  2021-07-06       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.